Oncology

Featured

Marina Kremyanskaya, MD, PhD, Icahn School of Medicine

Videos

Rusfertide Improves Hematocrit Control and Decreases Use of Phlebotomy Among Patients With PV

05/28/2024

Featuring Marina Kremyanskaya, MD, PhD

Featuring Marina Kremyanskaya, MD, Ph...

Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.

Marina Kremyanskaya, MD, PhD,...

05/28/2024

Oncology

Conference Coverage

Doublet vs Singlet Immunotherapy for Patients With Metastatic MSI-High Colorectal Cancer

05/24/2024

Michael Overman, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Overman, MD, discussed advantages associated with treating patients with MSI-high colorectal cancer with doublet immunotherapy.

At Great Debates and Updates in...

05/24/2024

Oncology

Conference Coverage

Hepatic Arterial Infusion Pump Therapy for Previously Treated Patients With Metastatic Colorectal Cancer

05/24/2024

Michael Lidsky, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Lidsky, MD, discussed ways researchers are working to overcome barriers to hepatic arterial infusion pump therapy limitations for patients with...

At Great Debates and Updates in...

05/24/2024

Oncology

Conference Coverage

Value of Germline Genetic Testing for All Patients With Gastrointestinal Cancers Irrespective of Tumor Origin

05/24/2024

Michael Hall, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Hall, MD, MS, discussed limitations to performing germline genetic testing on all patients with gastrointestinal cancers.

At Great Debates and Updates in...

05/24/2024

Oncology

Sarah Smith, Virginia Cancer Specialists

Videos

Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices

05/24/2024

Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...

Sarah Smith, BD, CNMT, discusses...

05/24/2024

Oncology

Conference Coverage

Transarterial Chemoembolization Plus Immunotherapy for Patients With Hepatocellular Carcinoma

05/23/2024

Adam Talenfeld, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Adam Talenfeld, MD, argued in favor of using transarterial chemoembolization alongside immune checkpoint blockade to treat patients with hepatocellular...

At Great Debates and Updates in...

05/23/2024

Oncology

Conference Coverage

Transarterial Chemoembolization Plus Immune Checkpoint Blockade for Patients With Hepatocellular Carcinoma

05/22/2024

James Harding, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, James Harding, MD, discussed results from the EMERALD-1 study which demonstrated that transarterial chemoembolization plus immune checkpoint blockade...

At Great Debates and Updates in...

05/22/2024

Oncology

Conference Coverage

Consideration of Long Course Radiation for Patients With Rectal Cancer

05/21/2024

Jennifer Wo, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Jennifer Wo, MD, discussed use of long course neoadjuvant radiation therapy for the treatment of patients with rectal cancer.

At Great Debates and Updates in...

05/21/2024

Oncology

Conference Coverage

PD-1 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancers

05/18/2024

Ryan Moy, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Ryan Moy, MD, PhD, discussed first-line use of PD-1 inhibitors for the treatment of patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Conference Coverage

Claudin-18.2 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancer

05/18/2024

Samuel Cytryn, MD

At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Samuel Cytryn, MD, discussed first-line use of claudin-18.2 inhibitors for patients with gastroesophageal cancers.

At Great Debates and Updates in...

05/18/2024

Oncology

Conference Coverage

Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?

05/15/2024

Edward Garon, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates...

05/15/2024

Oncology

Insights From the ESMO Congress

Conference Coverage

Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma

11/22/2023

Stephanie Holland

Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.

Biomarker analyses from patients...

11/22/2023

Oncology

Quiz

Tisotumab Vedotin for Cervical Cancer

11/21/2023

Oncology

Conference Coverage

Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma

11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...

Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.

Juergen C. Becker, MD, PhD,...

11/20/2023

Oncology

Arlene Siefker-Radtke, MD, MD Anderson Cancer Center

Videos

Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma

11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...

Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.

Arlene Siefker-Radtke, MD,...

11/16/2023

Oncology

Videos

Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer

11/16/2023

Featuring Sara Lonardi, MD

Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.

Sara Lonardi, MD, shares results...

11/16/2023

Oncology

Kohei Shitara, MD, PhD, National Cancer Center Hospital East

Videos

Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer

11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...

In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.

In the KEYNOTE-585 study,...

11/14/2023

Oncology

Quiz

Adjuvant Radiotherapy Following Radical Prostatectomy

11/13/2023

Allison Casey

Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.

Test your knowledge on the...

11/13/2023

Oncology

Conference Coverage

Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer

11/10/2023

Featuring Oleg Gluz, MD

Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.

Oleg Gluz, MD, Evangelical...

11/10/2023

Oncology

News

Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy

11/10/2023

Allison Casey

Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.

Results from the phase 3...

11/10/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Allison Casey

Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Niraparib plus abiraterone...

11/10/2023

Oncology

Insights From the ASCO Annual Meeting

News

Azacitidine Plus Ruxolitinib Demonstrates ‘Promising’ Efficacy in Myelofibrosis

05/31/2024

Amber Denham

Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.

Long-term follow-up results from...

05/31/2024

Oncology

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results from the INAVO120 trial, inavolisib plus palbociclib and fulvestrant sustained clinical benefit beyond disease progression among patients with PIK3A-mutated, HR-positive, HER2-negative, locally advanced or...

According to updated results...

05/31/2024

Oncology

News

Pelabresib Plus Ruxolitinib Reduces Splenomegaly, Improves Anemia Among JAK-Inhibitor-Naive Patients With Myelofibrosis

05/30/2024

Amber Denham

Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...

Pelabresib plus ruxolitinib...

05/30/2024

Oncology

News

R-CHOP Plus Venetoclax Fails to Improve PFS Among Patients With DLBCL With Double Expressor Lymphoma

05/29/2024

Amber Denham

Venetoclax added to R-CHOP among patients with DLBCL with expression of MYC and BCL2 did not improve progression-free survival, and caused higher toxicity, according to a phase 2 study presented at the 2024 ASCO Annual Meeting.

Venetoclax added to R-CHOP among...

05/29/2024

Oncology

News

Carfilzomib Plus Rituximab, Ifosfamide, Carboplatin and Etoposide Demonstrates Efficacy for Patients With Transplant-Eligible R/R DLBCL

05/29/2024

Amber Denham

According to research presented at the 2024 ASCO Annual Meeting, carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide shows high CR rates and longer PFS among patients with relapsed/refractory DLBCL, especially for non-GCB DLBCL...

According to research presented...

05/29/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan With or Without Pertuzumab Shows Promise For Previously Untreated Patients With HER2-Positive Metastatic Breast Cancer

05/28/2024

Allison Casey

According to a phase 1b/2 trial, trastuzumab deruxtecan with or without pertuzumab showed promising efficacy among previously untreated patients with HER2-positive metastatic breast cancer, with safety profiles consistent with the known...

According to a phase 1b/2 trial,...

05/28/2024

Oncology

Conference Coverage

Addition of Stereotactic Body Radiotherapy to Chemotherapy for Patients With Inoperable, Locally Advanced Cholangiocarcinoma

05/28/2024

Allison Casey

According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is...

According to a phase 2 trial...

05/28/2024

Oncology

Conference Coverage

Ipilimumab Biosimilar Added to Sintilimab in Neoadjuvant Setting Improves Response Rates Among Patients With MSI-H/dMMR Colorectal Cancer

05/28/2024

Allison Casey

According to results from a phase Ib study, the addition of an ipilimumab biosimilar (IBI310) to sintilimab in the neoadjuvant setting improved pCR rates among patients with locally advanced, resectable microsatellite...

According to results from a...

05/28/2024

Oncology

Conference Coverage

Sacituzumab Tirumotecan Improves Survival Outcomes Among Patients With Advanced Triple-Negative Breast Cancer

05/28/2024

Allison Casey

According to phase 3 data to be presented at the 2024 ASCO Annual Meeting, sacituzumab tirumotecan improved progression-free survival and overall survival compared to chemotherapy with manageable safety for heavily pre-treated patients with...

According to phase 3 data to be...

05/28/2024

Oncology

Videos

Triplet vs Quadruplet Regimen for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

08/28/2023

Featuring Stefan Knop, MD

Stefan Knop, MD, presents initial results from a randomized phase 3 study of triplet vs quadruplet therapeutic regimen for patients with newly diagnosed transplant-eligible multiple myeloma.

Stefan Knop, MD, presents...

08/28/2023

Oncology

Biological Pathway Reviews

Live Meetings

Recent News

News

Azacitidine Plus Ruxolitinib Demonstrates ‘Promising’ Efficacy in Myelofibrosis

05/31/2024

Amber Denham

Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.

Long-term follow-up results from...

05/31/2024

Oncology

News

Cytopenias/Proliferation Define Outcomes for Patients With Primary MF and MF from Essential Thrombocythemia or PV

05/31/2024

Amber Denham

Cytopenias and/or proliferation, over JAK2 allele burden, correlate with outcomes of patients with primary myelofibrosis and with myelofibrosis from essential thrombocythemia or polycythemia vera, according to data presented at the 2024...

Cytopenias and/or proliferation,...

05/31/2024

Oncology

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results...

05/31/2024

Oncology

News

Oral Decitabine and Cedazuridine Plus Venetoclax Shows Efficacy, Safety for Older or Unfit Patients With AML

05/31/2024

By Gina Tomaine

Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.

Decitabine and cedazuridine plus...

05/31/2024

Oncology

News

Pelabresib Plus Ruxolitinib Reduces Splenomegaly, Improves Anemia Among JAK-Inhibitor-Naive Patients With Myelofibrosis

05/30/2024

Amber Denham

Pelabresib plus ruxolitinib...

05/30/2024

Oncology

News

R-CHOP Plus Venetoclax Fails to Improve PFS Among Patients With DLBCL With Double Expressor Lymphoma

05/29/2024

Amber Denham

Venetoclax added to R-CHOP among...

05/29/2024

Oncology

News

Carfilzomib Plus Rituximab, Ifosfamide, Carboplatin and Etoposide Demonstrates Efficacy for Patients With Transplant-Eligible R/R DLBCL

05/29/2024

Amber Denham

According to research presented...

05/29/2024

Oncology

News

First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Patients With Advanced Extranodal Natural Killer/T-Cell Lymphoma

05/29/2024

Amber Denham

According to results from a phase 2 trial, the combination of sintilimab with pegaspargase, gemcitabine, and oxaliplatin exhibits efficacy and safety as a frontline regimen among patients with advanced extranodal natural killer/T-cell...

According to results from a...

05/29/2024

Oncology

News

Abemaciclib Plus Nonsteroidal Aromatase Inhibitor Improved Survival Outcomes Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

05/23/2024

Stephanie Holland

According to final overall survival results from the MONARCH 3 study, abemaciclib plus a nonsteroidal aromatase inhibitor improved overall survival and prolonged progression-free survival among patients with HR-positive, HER2-negative...

According to final overall...

05/23/2024

Oncology

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...

According to results from the...

05/23/2024

Oncology